[{"orgOrder":0,"company":"CrossLink Life Sciences","sponsor":"Heron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Bupivacaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"CrossLink Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"CrossLink Life Sciences \/ Heron Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"CrossLink Life Sciences \/ Heron Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by CrossLink Life Sciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The partnership aims to expand the sales network supporting Zynrelef (bupivacaine and meloxicam) extended-release solution, the first and only dual-acting local anesthetic, for post-operative pain.

                          Brand Name : Zynrelef

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 07, 2024

                          Lead Product(s) : Bupivacaine,Meloxicam

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Heron Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank